Oral ONC201 in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-10-25
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of Oral ONC201 in treating patients
with advanced solid tumors. Oral ONC201 may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth.
Phase:
Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey